Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
83% Decrease in Infant RSV Hospitalisation with Nirsevimab
In the Phase IIIb HARMONIE trial, nirsevimab (Beyfortus) drastically reduced infant respiratory syncitial virus (RSV) hospitalisations by 83%, and reduced all-cause lower respiratory tract infection hospitalisations by 58% (n = 8058). RSV is the most common cause of respiratory tract…
